Swiss pharma company reveals SCOTUS appeal plans

Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Swiss watchdog investigates Novartis over patent use

20 September 2022 Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Big Pharma

Federal Circuit denies Novartis’ bid to halt generics

29 September 2022 Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Americas

Generic maker hits back at Novartis stay bid

6 October 2022 HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.

More on this story

Big Pharma

Swiss watchdog investigates Novartis over patent use

20 September 2022 Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Big Pharma

Federal Circuit denies Novartis’ bid to halt generics

29 September 2022 Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Americas

Generic maker hits back at Novartis stay bid

More on this story

Big Pharma

Swiss watchdog investigates Novartis over patent use

20 September 2022 Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Big Pharma

Federal Circuit denies Novartis’ bid to halt generics

29 September 2022 Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.

Americas

Generic maker hits back at Novartis stay bid